Profile data is unavailable for this security.
About the company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
- Revenue in USD (TTM)12.99m
- Net income in USD-74.39m
- Incorporated2018
- Employees73.00
- LocationArbutus Biopharma Corp701 Veterans CircleWARMINSTER 18974United StatesUSA
- Phone+1 (267) 469-0914
- Fax+1 (604) 419-3201
- Websitehttps://www.arbutusbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alector Inc | 97.06m | -130.39m | 512.77m | 244.00 | -- | 3.37 | -- | 5.28 | -1.56 | -1.56 | 1.16 | 1.58 | 0.1377 | -- | 75.04 | 397,795.10 | -18.50 | -20.00 | -22.92 | -23.81 | -- | -- | -134.34 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Allogene Therapeutics Inc | 95.00k | -327.27m | 513.88m | 232.00 | -- | 0.991 | -- | 5,409.23 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
ProKidney Corp | 0.00 | -35.47m | 519.00m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Altimmune Inc | 426.00k | -88.45m | 521.79m | 59.00 | -- | 2.68 | -- | 1,224.86 | -1.64 | -1.64 | 0.008 | 2.75 | 0.002 | -- | 0.6636 | 7,220.34 | -42.36 | -39.62 | -45.55 | -42.58 | -- | -- | -20,762.21 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
Korro Bio Inc | 0.00 | -81.17m | 523.72m | 101.00 | -- | 2.66 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
PetIQ Inc | 1.10bn | 2.13m | 524.47m | 1.93k | 287.60 | 2.35 | 10.68 | 0.4759 | 0.0614 | 0.0614 | 35.69 | 7.52 | 1.31 | 5.63 | 8.46 | 570,079.10 | 0.301 | -4.32 | 0.3777 | -5.23 | 22.94 | 20.05 | 0.2304 | -3.66 | 1.43 | 1.74 | 0.6671 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
Larimar Therapeutics Inc | 0.00 | -36.95m | 525.71m | 42.00 | -- | 4.43 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Arbutus Biopharma Corp | 12.99m | -74.39m | 528.41m | 73.00 | -- | 4.40 | -- | 40.69 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
Shattuck Labs Inc | 2.72m | -85.08m | 531.62m | 75.00 | -- | 4.12 | -- | 195.81 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Avid Bioservices Inc | 136.74m | -17.96m | 534.50m | 365.00 | -- | 2.97 | -- | 3.91 | -0.284 | -0.284 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -3.97 | 10.73 | -6.03 | 15.22 | 7.47 | 22.72 | -13.13 | 25.92 | 0.3097 | -5.04 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
Astria Therapeutics Inc | 0.00 | -72.89m | 536.50m | 59.00 | -- | 2.71 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.93m | -64.37m | 537.91m | 25.00 | -- | -- | -- | 278.42 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Verve Therapeutics Inc | 11.76m | -200.07m | 537.95m | 255.00 | -- | 0.8764 | -- | 45.75 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Humacyte Inc | 0.00 | -110.78m | 540.64m | 183.00 | -- | 34.75 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Celcuity Inc | 0.00 | -63.78m | 543.28m | 55.00 | -- | 3.26 | -- | -- | -2.70 | -2.70 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -34.76 | -37.32 | -36.88 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2095 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Holder | Shares | % Held |
---|---|---|
Whitefort Capital Management, LPas of 31 Dec 2023 | 13.20m | 7.35% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 9.58m | 5.34% |
Two Seas Capital LPas of 31 Dec 2023 | 9.04m | 5.04% |
Morgan Stanley Investment Management, Inc.as of 31 Dec 2023 | 6.39m | 3.56% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 5.80m | 3.23% |
Woodline Partners LPas of 31 Dec 2023 | 4.72m | 2.63% |
Hudson Bay Capital Management LPas of 31 Dec 2023 | 4.14m | 2.31% |
Adar1 Capital Management LLCas of 31 Dec 2023 | 3.47m | 1.93% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.82m | 1.57% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.40m | 1.34% |